In the global race to develop a potential vaccine for coronavirus, India is not that far behind. In a recent development, four Indian vaccines are likely to be tried on humans soon.
As per a report published in a leading daily, out of all the Indian vaccines currently at different stages of progress, four have shown promising results and will be soon tested on humans.
Quoting, Renu Swarup, Secretary, Department of Biotechnology, India’s nodal agency for coronavirus vaccine development, the report further mentioned that the four vaccines are at the advanced stage of the development and within a span of three to six months, they will enter phase 1 of clinical trials.
In this phase, the potential vaccine will be tested on a small group of participants to see if the drug is safe and effective or not.
Currently, more than 30 Indian coronavirus vaccines are at various stages of development. Last week, Principal Scientific Adviser K VijayRaghavan said that out of all, 20 are keeping a good pace.
Globally, more than 100 potential coronavirus vaccines are being tested in different laboratories. The competition is getting tough as new entrants are regularly setting their foot into this race. British American Tobacco (BAT) and Indian Patanjali group has also claimed to have developed a cure for the fatal disease.
Last week, Ramdev’s Patanjali group got a nod from authorities to conduct clinical trials of its product that they claim can help in treating coronavirus. The Patanjali group, known for its ayurvedic supplements and products will begin its trial in Indore and Jaipur.
Sun Pharmaceutical Industries also received Indian regulatory’s approval on Friday to start clinical trials of a pancreatitis drug, Nafamostat on coronavirus infected patient. The drug is being considered helpful in combating coronavirus by scientists of the University of Tokyo and Leibniz Institute for Primate Research, Germany.
All eyes are on US-based biotech company Modera Inc, which is currently leading the race of developing a potential vaccine for coronavirus. The company’s vaccine has completed its stage 1 of clinal trials and is all set to enter phase 2 of trials on 600 individuals.